Clinical Trial Detail

NCT ID NCT03417154
Title Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota

acute myeloid leukemia

myelodysplastic syndrome


Cyclophosphamide + Nivolumab

Age Groups: senior adult

No variant requirements are available.